Options
Novel Approaches of Inflammatory Residual Risk Management in Cardiovascular Diseases
Woltersdorf, Lukas |
Recenzentas / Reviewer | |
Komisijos pirmininkas / Committee Chairman | |
Komisijos narys / Committee Member | |
Komisijos narys / Committee Member | |
Komisijos narys / Committee Member |
ABSTRACT
AIM: To assess the effect of novel approaches regarding the treatment of inflammatory residual risk.
OBJECTIVES: 1. Identifying the impact of hsCRP and IL-6 on cardiovascular disease. 2. Analyzing the effect of colchicine and methotrexate in cardiovascular diseases. 3. Examine the role of IL-1 modulators for the treatment of cardiovascular diseases. 4. Analyzing the significance of IL-6 modulators as a novel approach.
MATERIALS AND METHODS: A search for Articles from databases like MEDLINE, PubMed and Google Scholar were conducted. The keywords used during the search were “Residual risk” OR “Cardiovascular disease” OR “Atherosclerosis” AND “Inflammation” OR “Inflammatory pathway” OR “Inflammatory risk” OR “Interleukin-1” OR “Interleukin-6” OR “hsCRP” AND “Treatment” OR “Statin” OR “Canakinumab” OR “Monoclonal antibody” OR “Colchicine” OR “Methotrexate” OR “Tocilizumab” OR “Anakinra” OR “Ziltivekimab”. The articles were selected via specific inclusion and exclusion criteria. 20 articles were finally used for this review.
RESULTS: Randomized clinical trials, systemic and literature reviews and retrospective studies were reviewed. After the initial search, 20 studies were selected. Besides the investigation of the impact of inflammatory markers like hsCRP, IL-6 and IL-1 on the outcome of residual cardiovascular risk, the role of novel management approaches regarding inflammatory residual risk were assessed. This includes IL-1 and IL-6 modulators, colchicine and methotrexate.
CONCLUSION: 1. HsCRP and IL-6 are powerful biomarkers as well as good predictors for cardiovascular events. 2. The inflammatory pathway should be evaluated as a whole, rather than each individually. 3. IL-1 and IL-6 modulators show great potential for novel therapeutic options in inflammatory residual risk management. 4. Colchicine as a therapeutic option for further cardiovascular risk reduction shows promising results. 5. Methotrexate has no usefulness in cardiovascular risk management since it shows a greater harm than a benefit.
Santrauka
Tyrimo tikslas: Įvertinti naujų metodų poveikį uždegiminės liekamosios rizikos gydymui.
Tyrimo uždaviniai: 1. HsCRP ir IL-6 poveikio širdies ir kraujagyslių ligoms nustatymas. 2. Kolchicino ir metotreksato poveikio širdies ir kraujagyslių ligoms analizė. 3. Ištirti IL-1 moduliatorių vaidmenį gydant širdies ir kraujagyslių ligas. 4. IL-6 moduliatorių, kaip naujo požiūrio, reikšmės analizė.
Tyrimo metodika, rezultatai ir išvados: Šiai sisteminei apžvalgai buvo atrinkta 20 tyrimų iš tokių duomenų bazių kaip PubMed ir Google Scholar. Ištirtas hsCRP ir IL-6 vaidmuo likutinei kardiovaskulinei rizikai. Be to, buvo išanalizuoti nauji terapiniai metodai, skirti valdyti likutinę uždegiminę riziką. Apibendrinant galima pasakyti, kad uždegiminiai žymenys, tokie kaip hsCRP ir IL-6, yra labai svarbūs vertinant liekamąją uždegimo riziką. Be to, nauji metodai, tokie kaip IL-1/6 inhibitoriai ir kolchicinas, duoda daug žadančių rezultatų.